DAPK1 genepromoter hypermethylation demonstrated an AUC of 0.692 (95% CI=0.591-0.793, P=0.002) with64.4% sensitivity and 66.7% specificity, while CAVIN3 gene promoter hypermethylation wasnot able to distinguish metastatic BC patients from non-metastatic types. This evidence concerns the gene CAVIN3 and breast cancer.